DarioHealth (NASDAQ: DRIO), a leader in the global digital therapeutics (“DTx”) market, has presented results from its recent research showing impact of DRIO solutions to support people living in rural areas by delivering lasting health improvements. According to the presentation, the research focused on Dario’s ability to improve the health of members in rural areas, comparing results with those from urban counterparts; the results showed the solutions were equally effective. The information was presented at the Association of Diabetes Care and Education Specialists (“ADCES”) annual conference this week. In the announcement, the company noted living in rural areas is often associated with poor health, which can be aggravated by having less access to care and dealing with lower socioeconomic status. Dario’s integrated suite of chronic condition solutions helps people manage their health and care between doctors’ visits, a feature that could be highly beneficial for those living in rural areas. Dario’s research examined blood glucose data from members with high-risk type 2 diabetes living in urban areas to members living in rural areas and compared average levels of glycemic control over time; results indicated that both groups significantly reduced and maintained their average blood glucose levels, with no statistical difference between the rural and nonrural members. “Digital health represents an enormous opportunity to democratize access to better health if we build solutions that acknowledge the unique experiences of people across the country, including those outside of urban and suburban areas,” said Dario chief medical officer Omar Manejwala, MD, in the press release. “This new research shows Dario has potential to greatly improve self-care in rural populations by providing digital health tools that speak to individuals in relevant and meaningful ways no matter their location.”
To view the full press release, visit https://ibn.fm/kEy3p
About DarioHealth Corp.
DarioHealth is a leading digital therapeutics (“DTx”) company revolutionizing how people with chronic conditions manage their health through a user-centric, multichronic condition platform. The company’s platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain and behavioral health. DRIO’s user-centric platform offers people continuous and customized care for health, disrupting the traditional episodic approach to healthcare. This approach empowers people to holistically adapt their lifestyles for sustainable behavior change, driving exceptional user satisfaction, retention and results. Dario provides its highly user rated solutions globally to health plans and other payors, self-insured employers, providers of care and directly to consumers. For more information about the company, please visit www.DarioHealth.com.
NOTE TO INVESTORS: The latest news and updates relating to DRIO are available in the company’s newsroom at http://ibn.fm/DRIO
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.
As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork.
